Pharmacokinetics of intravenous piperacillin/tazobactam among patients with peritoneal dialysis-associated peritonitis

Abstract

Currently, pharmacokinetic information on intravenous (IV) piperacillin/tazobactam in patients with peritoneal dialysis-associated peritonitis (PD peritonitis) is limited. This study employed a prospective single-dose pharmacokinetic design to assess the pharmacokinetics of IV piperacillin/tazobactam in these patients. Four patients with PD peritonitis who received an IV loading dose of 4000 mg/500 mg piperacillin/tazobactam were enrolled in this study. The concentrations of piperacillin and tazobactam in plasma, peritoneal dialysis fluid (PDF) and urine were determined by high-performance liquid chromatography. Non-compartmental methods were used for pharmacokinetic analysis. During a 6-h dwell time for chronic ambulatory peritoneal dialysis (CAPD), 9.23 ± 4.01% of the piperacillin was recovered in the PDF. This result is greater than that observed in patients without peritonitis in prior research. Piperacillin’s PD clearance (CL_PD), steady-state volume of distribution (Vss) and terminal half-life (t _1/2) were 5.79 ± 2.55 mL/min, 24.35 ± 11.26 L and 5.74 ± 1.53 h, respectively. These values are also higher than those of patients without peritonitis in a prior study. Eight hours following the loading dosage, the plasma and PDF piperacillin concentrations of all patients (98.25 ± 26.03 and 52.70 ± 22.99 mg/L, respectively) surpassed the Pseudomonas aeruginosa and Enterobacterales Clinical and Laboratory Standards Institute susceptible breakpoints. In summary, the CL_PD, Vss and t _1/2 for piperacillin were found to be greater in patients with PD peritonitis than in CAPD patients without peritonitis when compared with the results of a previous study. The IV loading dose of 4000 mg/500 mg piperacillin/tazobactam is sufficient to treat peritonitis caused by susceptible P. aeruginosa and Enterobacterales. The multiple-dose pharmacokinetics of IV piperacillin and tazobactam in this specific patient group should be further investigated.

Keywords

Peritoneal dialysis peritoneal dialysis-associated peritonitis pharmacokinetics piperacillin/tazobactam

Get full access to this article

View all access options for this article.

References

Chow

Cho

, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int 2022; 42(2): 110–153.

Al Sahlawi

Bargman

Perl

. Peritoneal dialysis-associated peritonitis: suggestions for management and mistakes to avoid. Kidney Med 2020; 2(4): 467–475.

Elwell

Bailie

Manley

. Correlation of intraperitoneal antibiotic pharmacokinetics and peritoneal membrane transport characteristics. Perit Dial Int 2000; 20(6): 694–698.

Low

Gopalakrishna

Lye

. Pharmacokinetics of once daily intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 2000; 11(6): 1117–1121.

Salzer

. Peritoneal dialysis-related peritonitis: challenges and solutions. Int J Nephrol Renovasc Dis 2018; 11: 173–186.

Feng

Yang

, et al. Escherichia coli Peritonitis in peritoneal dialysis: the prevalence, antibiotic resistance and clinical outcomes in a South China dialysis center. Perit Dial Int 2014; 34(3): 308–316.

Zaidenstein

Weissgarten

Dishi

, et al. Pharmacokinetics of intraperitoneal piperacillin/tazobactam in patients on peritoneal dialysis with and without Pseudomonas peritonitis. Perit Dial Int 2000; 20(2): 227–231.

Debruyne

Ryckelynck

Hurault De Ligny

, et al. Pharmacokinetics of piperacillin in patients on peritoneal dialysis with and without peritonitis. J Pharm Sci 1990; 79(2): 99–102.

Johnson

Halstenson

Kelloway

, et al. Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin Pharmacol Ther 1992; 51 (1): 32–41.

10.

Ocampo

Hoyt

Wadgaonkar

, et al. Determination of tazobactam and piperacillin in human plasma, serum, bile and urine by gradient elution reversed-phase high-performance liquid chromatography. J Chromatogr 1989; 496(1): 167–179.

11.

Tucker

. Measurement of the renal clearance of drugs. Br J Clin Pharmacol 1981; 12(6): 761–770.

12.

Drusano

. Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. Nat Rev Microbiol 2004; 2(4): 289–300.

13.

Hayashi

Roberts

Paterson

, et al. Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opin Drug Metab Toxicol 2010; 6(8): 1017–1031.

14.

CLSI. Performance standards for antimicrobial susceptibility testing. 32nd ed. CLSI supplement M100. Clinical and Laboratory Standards Institute; 2022.

15.

Keller

Reetze

Schollmeyer

. Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations. Clin Pharmacokinet 1990; 18(2): 104–117.

16.

Yung

Chan

. Pathophysiological changes to the peritoneal membrane during PD-related peritonitis: the role of mesothelial cells. Mediators Inflamm 2012; 2012: 484167.